Category

Archives

Blog of Signaling Pathways

Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: a retro-prospective observational study

72 views | Jul 04 2022

Maria Livia Del Giudice et al. thought that Kd56 was an effective and well tolerated regimen in highly pretreated and elderly patients with a good safety profile. [Read the Full Post]

Reengineering Ponatinib to Minimize Cardiovascular Toxicity

141 views | Jul 03 2022

Anna Pavlovna Hnatiuk et al. suggested that ponatinib cardiotoxicity was mediated by a few kinases, some of which were previously unassociated with cardiovascular disease. [Read the Full Post]

The impact of emricasan on chronic liver diseases: current data

60 views | Jul 03 2022

Vasileios Lekakis et al. showed that as emricasan treatment appeared safe and well-tolerated, irrespective the severity of liver disease, more studies were required to clarify better these subgroups of patients who might benefit most from this drug. [Read the Full Post]

Single-Molecule Sensing of an Anticancer Therapeutic Protein-Protein Interaction Using the Chemically Modified OmpG Nanopore

55 views | Jul 02 2022

Hye-Jin Hwang et al. found that the chemically modified OmpG nanopore can serve as a valuable sensor platform for ultrasensitive, rapid, and single-molecule-based drug screening against protein-protein interactions, which are therapeutic targets for various diseases. [Read the Full Post]

Restoration of Cullin3 gene expression enhances the improved effects of sonic hedgehog signaling activation for hypertension and attenuates the dysfunction of vascular smooth muscle cells

9 views | Jul 02 2022

Jian Shen et al. found that restoration of CUL3 gene expression protected against hypertension through enhancing the effects of SHH activation in inhibition of apoptosis and oxidative stress for hypertension and alleviating the dysfunction of VSMCs. [Read the Full Post]

Class Ⅰ histone deacetylase inhibitor regulate of Mycobacteria-Driven guanylate-binding protein 1 gene expression

109 views | Jul 01 2022

Meili Wei et al. showed that the CpG site of the GBP1 promoter was hypermethylated, and the methylation status of the GBP1 promoter did not change significantly upon Mtb infection. [Read the Full Post]

Caspase-3-induced activation of SREBP2 drives drug resistance via promotion of cholesterol biosynthesis in hepatocellular carcinoma

87 views | Jul 01 2022

Etienne H Mok et al. demonstrated that CSC populations in HCC expanded via CASP3-dependent, SREBP2-mediated cholesterol biosynthesis in response to tyrosine kinase inhibitor therapy and that targeting cholesterol biosynthesis could overcome acquired drug resistance. [Read the Full Post]

Glycine induces enhancement of bactericidal activity of neutrophils

45 views | Jun 30 2022

Shin-Hae Kang et al. suggested that glycine could be a useful agent for increasing neutrophil bacterial clearance. [Read the Full Post]

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies

93 views | Jun 30 2022

Christine M Minnar et al. demonstrated that the combination of entinostat and NHS-IL12 therapy elicited potent antitumor activity. [Read the Full Post]

Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma

36 views | Jun 29 2022

Zejia Yang et al. found that Afatinib and Copanlisib more effectively suppressed cell proliferation and survival of HPV-positive HNSCC in comparison to either treatment alone. [Read the Full Post]

Resistance to PI3κδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis

37 views | Jun 29 2022

Alberto J Arribas et al. presented a model of secondary resistance to PI3Kffinhibitors obtained by prolonged exposure of a splenic MZL cell line to idelalisib. [Read the Full Post]

Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer

34 views | Jun 28 2022

Sarah Sammons et al. discussed the data, the population studied and the population in which abemaciclib was approved as well as safety, tolerability, and dose reductions for practical management of these patients. [Read the Full Post]

Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib

85 views | Jun 27 2022

Fabio Scirocchi et al. reported that Cabozantinib might exert an immunostimulatory role by inducing immunogenic stress of prostate cancer cells and directly modulating dendritic cells (DCs). [Read the Full Post]

Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer

50 views | Jun 27 2022

Motahareh Mortazavi et al. reported that whole-genome analyses demonstrated the frequent involvement of aberrant activations of PI3K/AKT/mTOR pathway components in PDAC patients. [Read the Full Post]

Repression of HIV-1 reactivation mediated by CRISPR/dCas9-KRAB in lymphoid and myeloid cell models

134 views | Jun 26 2022

Lendel Correia da Costa et al. demonstrated that KRAB repressor protein was crucial to reactivation resistance phenotype. [Read the Full Post]

Histone Deacetylase Inhibitors Counteract CGRP Signaling and Pronociceptive Sensitization in a Rat Model of Medication Overuse Headache

110 views | Jun 26 2022

Matteo Urru et al. provided evidence for a key role of HDACs and epigenetics in MOH pathogenesis, highlighting the therapeutic potential of HDAC inhibition in the prevention of migraine chronification. [Read the Full Post]

The Application of ATR Kinase Inhibitor AZD6738 in Combination with Radiotherapy for the Treatment of Melanoma

62 views | Jun 24 2022

Maryam Talebpoor et al. provided insight into the impact of Ataxia Telangiectasia and Rad3-related kinase (ATR) inhibition on the potential role of this kinase in the suppression of melanoma cell proliferation. [Read the Full Post]

A randomized, placebo-controlled clinical trial of hydrogen/oxygen inhalation for non-alcoholic fatty liver disease

61 views | Jun 24 2022

Geru Tao et al. found that inhalation of hydrogen/oxygen improved serum lipid and liver enzymes. [Read the Full Post]

The PRC2 molecule EED is a target of epigenetic therapy for neuroblastoma

113 views | Jun 23 2022

Dilibaerguli Shaliman et al. suggested that inhibitory cell cycle-regulated gene sets were markedly up-regulated. [Read the Full Post]

Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405)

70 views | Jun 23 2022

Naoki Haratake et al. thought that pemetrexed should be administered without fail as a sequential treatment to improve the prognosis of EGFR-mutated NSCLC as well as like EGFR-tyrosine kinase inhibitors. [Read the Full Post]